PubMed
Alpha-MSH tripeptide analogs reduce inflammation
Luger et al., 2004
Immune SupportResearch OnlyB
KPV
α-MSH C-terminal tripeptide
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- B
- Experience
- 99
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About KPV
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
- Category
- Immune Support
- Regulatory status
- Research Only
- Also known as
- α-MSH C-terminal tripeptide
- Self-reports
- 54
Community
What 54 users report
54 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
210
Mood
210
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.2–3 mg
0.2–0.4 mg
116
0.4–0.6 mg
89
0.6–1 mg
3
1–2 mg
1
2–3 mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 60 days · Based on 43 repeat reporters
Research
Cited research (6)
Source
PubMed
KPV tripeptide exerts anti-inflammatory effects in intestinal epithelial cells
Brzoska et al., 2010
PubMed
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser et al., 2008
PubMed
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells
Elliott et al., 2004
ClinicalTrials.gov
KPV peptide studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
The neuroimmunomodulatory peptide alpha-MSH
Ichiyama et al., 2000
Tools
Explore more
Explore
More ways to learn about KPV from observational PeptIQ data.
Help
Frequently asked
What do PeptIQ users report about KPV?
This page summarizes 54 anonymized self-reports from PeptIQ users who track KPV, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for KPV?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for KPV?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is KPV safe to use?
This wiki does not assess safety or recommend use. KPV is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of KPV?
Research, primarily in animal models, suggests KPV may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of KPV?
KPV is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified KPV as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of KPV?
The safety and effectiveness of KPV have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on KPV?
While there are over 200 published studies on KPV, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source